Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Segezha Group may build a plant to produce CLT panels in the Irkutsk region

4/6/23 SGZH

X5 Retail Group closed the last Karusel hypermarket

4/6/23 FIVE

Tatneft buys 50% of the Turkish fuel company Aytemiz Akaryaki

4/6/23 TATN

Bulgarian regulator fined Lukoil again

4/6/23 LKOH

Samolet plans to build the first project in the Far East in 2025

4/6/23 SMLT

MTS bought from Sistema JSFC advertising platform Segmento

4/6/23 MTSS

Ozon abandoned the project of private ads service

4/5/23 OZON

FedEx announced a quarterly dividend

4/5/23 FDX

Profit of driving school Svetofor according to RAS in 2022 increased by 25 times

4/5/23 SVET

Fesco set up a subsidiary in Belarus to develop import and export shipments

4/5/23 FESH